A Phase 3 interventional study of KamRAB - HRIG in Rabies, sponsored by Kamada, Ltd.. Completed at 1 site in United States. Open to participants aged 0 Years to 17 Years. Per ClinicalTrials.gov, last updated 2021-09-05.
Sponsored by Kamada, Ltd. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies in Rabies with a site in United States — none open to participants now, none under way, none of them phase 3. Rabies · United States.
Among the 19 studies in Rabies with a site in United States, this one is the 16th largest by enrollment of the 17 interventional ones that give a count, is one of 4 that started in 2016, is the only one in phase 3, and was the 10th registered.
115 studies on the registry are indexed under Rabies; 12 are open to participants now.
Browse Rabies studies →None of the 19 studies in Rabies with a site in United States is open now. The open studies under Rabies, anywhere →
Of the 2 Rabies studies recruiting now, none set no upper age limit and 2 stop at 75 or younger; 1 takes children under 18; none take healthy volunteers.
This study: 0 Years to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 7 · Phase 3 2 · Phase 4 3
First in 2008; this study’s year is marked. 4 started in 2016.
This study's enrollment of 30 is below the median of 200 across 105 interventional studies indexed under Rabies.
Median enrollment 130 across the 17 interventional studies, 263 across the 2 observational. Of the 19 that completed or were terminated, 9 (47%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 19 have an industry lead sponsor. The 10 most frequent:
Kamada, Ltd. is the lead sponsor of 11 studies on the registry; none are open to participants now.
Kamada, Ltd. has 2 studies filed under Rabies — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 19 studies in Rabies with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The primary purpose of this study is to confirm the safety of KamRAB (Human Rabies Immunoglobulin) in children ages 0 months to \<17 years, when administered as part of post-Rabies Exposure Prophylaxis (PEP).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: KamRAB - HRIG
wound infiltration or IM injection
Frequency and severity of local and systemic adverse events occurring within 14 days of KamRAB treatment
Time frame: Within 14 days from treatment
Frequency and severity of local and systemic SAEs occurring within 84 days of KamRAB treatment
Time frame: Within 84 days of treatment
Ran from Aug 2016 to primary completion in Nov 2019, 39 months.
Of 22 phase 3 interventional studies under Rabies, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 21. This study's 39 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Kamada, Ltd.